News for hackers. Stuff that matters.
Re:The Mystery in the Medicine Cabinet: Acetaminophen, ibupr... by rao-v on Wednesday April 22, 2026 @12:40AM (#47859098)
Could somebody package Tylenol with a sufficient amount of NAC to de-risk it? I suspect such a formulation would not require trials?
Re:The Mystery in the Medicine Cabinet: Acetaminophen, ibupr... by djsavvy on Wednesday April 22, 2026 @01:29AM (#47859447)
See superscript 6 on the article. Apparently NAC might has side effects of its own.
Re:The Mystery in the Medicine Cabinet: Acetaminophen, ibupr... by keane on Wednesday April 22, 2026 @04:26AM (#47860690)
One of the side effects in a study in mice was inducing lung cancer: https://doi.org/10.1172/jci.insight.127647
Re:The Mystery in the Medicine Cabinet: Acetaminophen, ibupr... by rao-v on Wednesday April 22, 2026 @10:38PM (#47871735)
Ah
Re:The Mystery in the Medicine Cabinet: Acetaminophen, ibupr... by 986aignan on Wednesday April 22, 2026 @06:52AM (#47861709)
Certain esters have been found to be much safer (in mice, at least):

> The glutathione hepatic values in mice obtained by intraperitoneal injection of the ester are superimposable on controls and the oral LD50 was found to be greater than 2000 mg kg^-1 and the intraperitoneal LD50 was 1900 mg kg^-1 ...

That's for pyroglutamic and glutamic acid esters of paracetamol: https://pubmed.ncbi.nlm.nih.gov/8799871/

and more general analogs apparently can also be designed to not produce NAPQI:

> Thus, in 2020, N-sulpharyl-APAP prodrugs 39–40 (Fig. 11) were developed. [...] They are not hepatotoxic because they do not generate toxic metabolite NAPQI, even in concentrations equal to a toxic dose of APAP (600 mg kg^−1 in mice).

https://pubs.rsc.org/zh-tw/content/articlepdf/2024/ra/d4ra00... p. 9702.

These would probably require trials, though.